Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2005

Lesinski GB, Valentino D, Hade EM, Jones S, Magro C, Chaudhury AR, et al. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy. Cancer Immunol Immunother. 2005;54(9):815-25.

Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood. 2005;106(5):1538-43.

Breza TS, Magro CM. CD34 expression in primary cutaneous malignant melanoma: apropos of a case and review of the aberrant melanoma phenotype. J Cutan Pathol. 2005;32(10):685-9.

Aslan DL, H Gulbahce E, Pambuccian SE, J Manivel C, Jessurun J. Ki-67 immunoreactivity in the differential diagnosis of pulmonary neuroendocrine neoplasms in specimens with extensive crush artifact. Am J Clin Pathol. 2005;123(6):874-8.

Verma S, Nuovo GJ, Porcu P, Baiocchi RA, A Crowson N, Magro CM. Epstein-Barr virus- and human herpesvirus 8-associated primary cutaneous plasmablastic lymphoma in the setting of renal transplantation. J Cutan Pathol. 2005;32(1):35-9.

Lucarelli MR, Allen JN, Magro CM. Plasma cell mucositis of the distal airways. Thorax. 2005;60(2):173.

Magro CM, Calomeni EP, Nadasdy T, Shusterman BD, Pope-Harman AL, Ross P. Ultrastructure as a diagnostic adjunct in the evaluation of lung allograft biopsies. Ultrastruct Pathol. 2005;29(2):95-106.

Sdek P, Ying H, Chang DL, Qiu W, Zheng H, Touitou R, et al. MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell. 2005;20(5):699-708.

Ely S, Di Liberto M, Niesvizky R, Baughn LB, Cho HJ, Hatada EN, et al. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res. 2005;65(24):11345-53.

Gu Z, Rubin MA, Yang Y, Deprimo SE, Zhao H, Horvath S, et al. Reg IV: a promising marker of hormone refractory metastatic prostate cancer. Clin Cancer Res. 2005;11(6):2237-43.